当前位置： SCI文献检索 > ONCOGENE期刊下所有文献 > AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.

Abstract：

:Accumulating evidences have shown the association between aberrantly expressed microRNAs (miRs) and cancer, where these small regulatory RNAs appear to dictate the cell fate by regulating all the main biological processes. We demonstrated the responsibility of the circuitry connecting the oncomiR-221&222 with the tumor suppressors miR-126&126* in melanoma development and progression. According to the inverse correlation between endogenous miR-221&222 and miR-126&126*, respectively increasing or decreasing with malignancy, their enforced expression or silencing was sufficient for a reciprocal regulation. In line with the opposite roles of these miRs, protein analyses confirmed the reverse expression pattern of miR-126&126*-targeted genes that were induced by miR-221&222. Looking for a central player in this complex network, we revealed the dual regulation of AP2α, on one side directly targeted by miR-221&222 and on the other a transcriptional activator of miR-126&126*. We showed the chance of restoring miR-126&126* expression in metastatic melanoma to reduce the amount of mature intracellular heparin-binding EGF like growth factor, thus preventing promyelocytic leukemia zinc finger delocalization and maintaining its repression on miR-221&222 promoter. Thus, the low-residual quantity of these two miRs assures the release of AP2α expression, which in turn binds to and induces miR-126&126* transcription. All together these results point to an unbalanced ratio functional to melanoma malignancy between these two couples of miRs. During progression this balance gradually moves from miR-126&126* toward miR-221&222. This circuitry, besides confirming the central role of AP2α in orchestrating melanoma development and/or progression, further displays the significance of these miRs in cancer and the option of utilizing them for novel therapeutics.

journal_name

Oncogene

journal_title

Oncogene

authors

Felli N,Errico MC,Pedini F,Petrini M,Puglisi R,Bellenghi M,Boe A,Felicetti F,Mattia G,De Feo A,Bottero L,Tripodo C,Carè A

doi

10.1038/onc.2015.357

subject

Has Abstract

pub_date

2016-06-09 00:00:00

pages

3016-26

issue

eissn

0950-9232

issn

1476-5594

pii

onc2015357

journal_volume

pub_type

杂志文章

在线工具

AP2α controls the dynamic balance between miR-126&126* and miR-221&222 during melanoma progression.